NYSE: TFXTeleflex Inc Stock
$139.23-0.73 (-0.52%)
Updated Mar 19, 2025
TFX Price
$139.23
Fair Value Price
N/A
Market Cap
$6.46B
52 Week Low
$128.55
52 Week High
$249.91
P/E
93.44x
P/B
1.51x
P/S
2.74x
PEG
0.78x
Dividend Yield
0.98%
Revenue
$3.05B
Earnings
$69.68M
Gross Margin
55.9%
Operating Margin
5.2%
Profit Margin
2.3%
Debt to Equity
0.66
Operating Cash Flow
$636M
Beta
0.95
Next Earnings
Apr 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TFX Overview
Teleflex Incorporated manufactures single-use medical devices for critical care and surgical applications. Offerings include Arrow-branded vascular catheters, anesthesia products, surgical instruments, the UroLift System for treating urinary tract symptoms, respiratory products (oxygen and aerosol therapies, and ventilation management). The company serves hospitals and healthcare providers, and home care markets. Teleflex was incorporated in 1943 and is headquartered in Wayne, PA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TFX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important TFX news, forecast changes, insider trades & much more!
TFX News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TFX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TFX ($139.23) is trading above its intrinsic value of $70.30, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TFX is poor value based on its earnings relative to its share price (93.44x), compared to the US market average (31.13x)
P/E vs Market Valuation
TFX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more TFX due diligence checks available for Premium users.
Valuation
TFX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
93.44x
Industry
39.67x
Market
31.13x
TFX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TFX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
TFX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.51x
Industry
3.74x
TFX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TFX price to earnings growth (PEG)
For valuing profitable companies with growth potential
TFX is good value based... subscribe to Premium to read more.
PEG Value Valuation
TFX's financial health
Profit margin
Revenue
$795.4M
Net Income
-$136.7M
Profit Margin
-17.2%
TFX's Earnings (EBIT) of $158.54M... subscribe to Premium to read more.
Interest Coverage Financials
TFX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.1B
Liabilities
$2.8B
Debt to equity
0.66
TFX's short-term assets ($1.47B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TFX's long-term liabilities ($2.17B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TFX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TFX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$202.5M
Investing
-$23.1M
Financing
-$119.1M
TFX's operating cash flow ($635.74M)... subscribe to Premium to read more.
Debt Coverage Financials
TFX vs Medical Stocks
Teleflex Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.